Aprea Therapeutics
APRE
22 hedge funds and large institutions have $5.5M invested in Aprea Therapeutics in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
1.53% less ownership
Funds ownership: 38.38% → 36.85% (-1.5%)
21% less funds holding
Funds holding: 28 → 22 (-6)
35% less capital invested
Capital invested by funds: $8.48M → $5.5M (-$2.98M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$205K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$21.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.5K |
| 4 |
Morgan Stanley
New York
|
+$15.5K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$176 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$558K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.2K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$23K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.99K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$4.07K |
APRE Hedge Fund Activity: Q3 2024 in Review
22 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q3 2024, worth a combined $5.5M — down 35% from $8.48M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of APRE and 0 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $205K. The largest seller was Altium Capital Management, exiting entirely with an estimated $558K sold.
- 22 institutional investors held Aprea Therapeutics (APRE) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $5.5M of Aprea Therapeutics stock for Q3 2024, down 35% quarter-over-quarter.
- 0 funds opened new Aprea Therapeutics positions in Q3 2024 and 6 closed out, a net change of -6 holders.
- The largest Aprea Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $205K added.
- The largest Aprea Therapeutics seller in Q3 2024 was Altium Capital Management, an estimated $558K sold.
Based on aggregated 13F filings for Q3 2024.